Atrium Therapeutics
RNA11.5700.26% ( +0.030 )
Atrium Therapeutics (RNA)
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people...
- Open
- 11.530
- High
- 11.780
- Low
- 11.530
- Prev. Close
- 11.540
- Volume
- 13.48K
- Turnover
- 157.11K
- Avg Price
- 11.655
- Bid/Ask Ratio
- --
- Amplitude
- 2.17%
- 52wk High
- 73.060
- Volume Ratio
- 0.63
- Turnover Ratio
- 0.09%
Atrium Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 14, 2026Price forecast
$25.00116.08%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- StockTitan · Jul 20 at 08:58 AM
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | RNA Stock News
- Tip Ranks · Jul 16 at 04:45 AM
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)
- TradingView · Jul 14 at 04:23 PM
Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to start
- PUBT · Jul 14 at 05:40 AM
Atrium Therapeutics publishes investor presentation on precision RNA medicines for cardiac diseases
- StockTitan · Jul 13 at 09:30 PM
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome | RNA Stock News
- Unusual Whales · Jun 23 at 03:07 PM
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
